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H O W D O I ?
Banking feces: a new frontier for public blood banks?
Simon Mark Dahl Jørgensen ,1 Christian Lodberg Hvas,1 Jens Frederik Dahlerup,1 Susan Mikkelsen,4
Lars Ehlers,2 Lianna Hede Hammeken,2 Tine Rask Licht,3 Martin Iain Bahl,3 and Christian Erikstrup4
Fecal microbiota transplantation (FMT) is an effective
treatment for recurrent Clostridioides difficile infection
and is potentially beneficial in other microbiota-related
disorders. The provision of FMT in routine clinical
practice requires an extensive infrastructure that is
reliant on voluntary donors. Alongside an increasing
demand for FMT, the logistic barriers of a large-scale
donor-dependent operation and the difficulties among
health authorities to regulate FMT limit the dissemination
of sustainable FMT services. Blood centers are large
organizations that handle a multitude of donor-
dependent operations on a daily basis. Blood and feces
share many of the same dependencies, and feces may
present a new opportunity for the blood services to
handle. In this paper, we describe how an FMT service
may be established and embedded within the blood
service infrastructure, and we explain the benefits of
using blood donors as feces donors. We further explore
the current indications of FMT, the challenges related to
the lack of legislation, and the future perspectives for
blood banks to meet a new and increasing demand.
F
ecal microbiota transplantation (FMT) is the trans-
fer of an entire fecal microbial community from a
donor to a patient who has a disturbed or
depleted intestinal microbial ecosystem.1 The
technique has been known and practiced for centuries.
Records of crude FMT treatments date back to the fourth
century in China, where the consumption of a mixture of
fecal matter and water, referred to as “yellow soup,” was
used as a means to treat food poisoning and diarrhea.2,3 In
modern medicine, the first successful FMTs were reported
in 1958 by Eiseman and coworkers,4 who treated four
patients with pseudomembranous colitis caused by
Clostridioides (formerly Clostridium) difficile (CD), which
was unknown at that time. Since then, resolution rates of
70% to 90% following FMT for recurrent CD infection (rCDI)
have been consistently reported in both observational
studies5–9 and randomized trials.10–14
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During the past decade, the increased understanding of
the human intestinal microbiota and its role in health and
disease development have sparked a new interest in the use
of FMT. Disturbances of the gut microbiota have been asso-
ciated with a range of extraintestinal disorders such as obe-
sity, diabetes, and allergies.15,16 For disorders in which a
causal effect of the microbiota can be established, FMT
potentially offers a new treatment approach that, contrary to
antibiotic treatments, has a restorative intent.
The high success rate of FMT in treating rCDI has
prompted intense development of the treatment approach.
In recent years, the FMT procedure has undergone drastic
improvements, shifting from low-tech applications using
kitchen devices and fresh feces obtained from relatives to
capsules containing rigorously screened feces from healthy,
anonymous donors.17–19 While FMT procedures have been
developed and optimized, the widespread dissemination of
FMT to the broader public is limited by logistical barriers
and a struggle regarding the regulation of FMT by compe-
tent authorities.
A feasible solution to meet these challenges may be a
collaboration with national blood centers. Today, blood ser-
vice organizations are large and complex organizations that
handle blood donor recruitment, blood donation, and prod-
uct processing, testing, and release. They thereby secure the
blood components needed for lifesaving transfusions for mil-
lions of patients each year. Globally, an estimated 112.5 mil-
lion transfusions take place each year.20 The transfusion of
safe blood to patients is a necessary component of a modern
health care system, and a multitude of other treatments
depend on this process. Less than 100 years ago, blood dona-
tion and transfusion started out as initiatives driven by
pioneering doctors and altruistic volunteers.21 Similarly, this
is where FMT is today, with individual initiatives driven by a
few physicians. We point out that both the regulatory frame-
work and the principles of practice used by existing blood
service organizations are readily applicable to FMT services.
In the present paper, we report our experiences with
establishing an FMT service developed with the blood service
infrastructure. We focus on the steps involved in recruiting
and screening feces donors to produce ready-to-use fecal
suspensions. We describe the challenges related to the lack
of legislation and the future perspectives for blood banks to
meet a new and increasing demand for fecal transplantation.
INDICATIONS AND MODE OF ACTION
FOR FMT
The main indication for FMT is rCDI, refractory to the
standard treatment with metronidazole, vancomycin, or
fidaxomicin.22,23 The clinical symptoms of rCDI range from
persistent diarrhea to life-threatening pseudomembranous
colitis with megacolon. In several clinical trials, FMT has
proved superior to antibiotics for the treatment of rCDI with
resolution rates ranging from 70% to 90%.10–14 As a result,
European and US clinical guidelines now recommend FMT
as a second-line treatment for rCDI.22,23
The growing appreciation for FMT as a potential treat-
ment for intestinal microbiota disruption has generated an
increased interest in FMT for the treatment of other
microbiota-sensitive diseases. Numerous clinical trials are cur-
rently investigating FMT for other indications such as inflam-
matory bowel diseases,24–26 irritable bowel syndrome,27–29
hepatic encephalopathy,30 metabolic syndrome,31,32 graft-
versus-host disease,33 and multidrug-resistant infections.34
Despite promising results, the current evidence for the thera-
peutic effect of FMT on these conditions is weak or contradic-
tory. The long-term effects of FMT are sparsely described, and
adverse events are underreported.35,36
The mode of action of FMT remains elusive. Most of
our knowledge comes from studies of patients with rCDI,
where gut physiology normalization and symptom resolu-
tion occurs within days of the procedure.37 FMT drives a
variable engraftment of a donor-like bacterial community
that, however, does not necessarily determine the treatment
response.38 Well-defined bacterial cocktails may be success-
fully applied for the treatment of rCDI,39 but the effect may
rely on specific properties, such as bile salt hydrolase activ-
ity, shared by groups of bacteria rather than the presence or
absence of specific strains.40 Regarding other diseases such
as inflammatory bowel disease, irritable bowel syndrome,
hepatic encephalopathy, or graft-versus-host disease, which
all have less well-defined underlying etiologies, the compo-
sition of the transplanted microbes or the requirements for
specific strains may differ from those associated with the
treatment of rCDI. The intriguing finding that sterile-
filtrated fecal water is effective for rCDI41 suggests that
nonbacterial substances, such as metabolites, host factors,
or bacteriophages, contribute to the therapeutic effect.42
Recent studies identified bacterial metabolites, such as the
short-chain fatty acid valerate, as important key factors for
understanding the mode of action of FMT.43 Taken together,
the determinants for successful FMT are numerous and are
not restricted to the action of live intestinal bacteria. The
studies highlight the complexities through which FMT
exerts its modes of action.
INFRASTRUCTURE OF AN FMT SERVICE
An FMT service may be divided into three overall compo-
nents: 1) donor recruitment and screening, 2) laboratory
processing, and 3) clinical application. These components
greatly resemble the infrastructure needed to collect, pro-
cess, and provide other donor-dependent products such as
blood, plasma, stem cells, and sperm. In the following sec-
tion, we describe the steps needed to produce a ready-to-
use fecal suspension compliant with the European Tissue
and Cells Directive (EUTCD).19,44
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Donor recruitment with baseline characteristics and
prescreening
An FMT service greatly depends on access to healthy
donors. A sustained effort to recruit donors is necessary and
represents two related challenges: accessing enough poten-
tial donors and selecting only the healthy donors. We do
not know exactly what constitutes a healthy intestinal
microbiota. Prior studies that investigated the effects of
FMT mostly recruited healthy, normal-weight donors who
met several health-related criteria, such as the absence of
chronic diseases, allergies, high-risk behavior, depression,
family history of malignancy, and use of medication.10,12,17
Donor screening
Given the potential implications of transferring pathogenic
microorganisms, a cautious approach to screening has been
applied in most studies and guidelines.1,45–48 This is analo-
gous with the procedures employed by blood service orga-
nizations and emphasizes the need for voluntary
(i.e., unpaid) donations. Since the emergence of the HIV
epidemic in the 1980s and the unforeseen transmission of
HIV to recipients through blood or plasma-derived
products,49 the precautionary principle has been applied to
new and emerging potential threats to blood safety. The
precautionary principle aims to ensure that potential risks
to blood safety are mitigated by either the deferral of donors
(e.g., based on symptoms or travel history) through screen-
ing or by pathogen inactivation. While the precautionary
principle has helped to reduce the risk of transfusion-
transmitted infectious diseases to very low levels in most
high-income countries, avoiding unnecessary criteria and
testing that reduces the number of eligible donors is also
necessary. Because of the very low specificity of several
deferral criteria, the cost per quality-adjusted life year
gained is high for many of the criteria.50 For FMT, we still
know little about the optimal criteria and screening targets.
Consequently, all donors are screened for infections and
noninfectious diseases with an extensive panel that includes
blood and fecal tests as well as health questionnaires
(Table SS1, available as supporting information in the
online version of this paper).1,17,47,51 The risk of false-
positive test results is high, and the number of eligible
donors is reduced with an increase in screening parameters.
Papers that describe the recruitment and screening of FMT
donors report overall eligibility rates of 3%, which makes
donor recruitment an important limiting factor in FMT
operations.46,52 Eligible feces donors are tested repeatedly,
and, as with blood, their donations are quarantined until all
postdonation screening results have been approved.
Laboratory processing
Feces donors either produce fecal products at home or at
facilities provided by the FMT institution. When kept cooled
at 4C, the fecal microbial community remains stable for up
to 8 hours before any detectable changes occur.53 Accord-
ingly, home donations should preferably be delivered to the
FMT institution within 2 hours to ensure microbial viability
and quality while giving the time for the processing.19
Before being applicable for clinical use, the feces must
undergo a series of processing steps that preserve the
microbiota and render a uniform, ready-to-use fecal sus-
pension. The methods differ according to the intended
administration form, but the processing principles are simi-
lar; the fecal sample is first diluted in saline, homogenized,
and crude-filtered; then cryoprotectant glycerol or branched
carbohydrates are added. The fecal suspensions are then
dispersed into containers or capsules and stored at −80C
until use. Overall, the processing aims to preserve a fecal
microbiota composition similar to that of the crude,
unprocessed feces. Although the effects of each handling
step on factors such as viability and bacterial composition
are unknown, cryopreservation does not affect the clinical
efficacy of FMT in patients with rCDI.54 On the day of clini-
cal application, the frozen suspension is thawed before use.
The suspension is linked to the recipient in a database, and
the final package is then delivered at the clinical ward for
administration.
Clinical application
Fecal microbiota transplantation may be applied to either
the upper or the lower gastrointestinal tract. For the upper
tract, FMT may be administered by nasojejunal tube inser-
tion, gastroscopy, or acid-resistant capsules. For the lower
gastrointestinal tract, FMT may be administered by colonos-
copy, sigmoidoscopy, or retention enemas. Colonoscopy is
regarded as the gold standard,55 but the clear benefits of an
encapsulated FMT, which can be ingested by the patient
without the requirement for bowel lavage or hospitalization,
make this the most practical mode of application. As an
adjuvant treatment option to FMT, preceding bowel lavage
may be used to facilitate the passing of the residual gut
microbiota thereby reducing the recipient’s microbial
load.56
Implementing an FMT service in clinical practice is
time consuming and requires significant resources. Given
these practical implications, stool banks across the United
States, Europe, and Asia have been formed to meet the
increasing demand for fecal donations.46 Stool banks recruit
and screen donors, process the donations, and deliver a
standardized feces suspension ready for clinical use. This
offers clinical institutions an easy option to routinely
perform FMT.
Traceability and quality control
FMT should be handled and processed in a context of strict
quality control and auditing. From donor inclusion to FMT
administration, measures should be taken to ensure high-
quality standards and complete traceability. These measures
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include the proper education of staff, the validation of labo-
ratory procedures and equipment, and the recording of all
essential information throughout all of the steps. Core data
from the donation sample, results from sample testing and
processing and the link to the recipient should be retained
for 30 years to ensure traceability.44 Ideally, the require-
ments for quality control should be ensured by regulation
and inspection by the health authorities as elaborated
below.
FECAL MICROBIOTA TRANSPLANTATION:
A REGULATORY STRUGGLE
To assure a high level of safety and quality, the regulation of
FMT and its related procedures by competent authorities is
pivotal.
The regulation of FMT remains controversial and varies
from nonexistent to very strict among countries. Since July
2016, in the United States, the US Food and Drug Adminis-
tration (FDA) has regulated FMT as an investigational new
drug (IND) with a legal exception applying to hospital phy-
sicians who treat patients with rCDI refractory to standard
treatment.57,58 To perform FMT for diseases other than
rCDI, institutions are required to submit an IND applica-
tion. This poses a marked limitation to the clinical and sci-
entific application of FMT. The enforcement exception for
FMT for rCDI form the sole regulatory framework for US
FMT institutions to operate within. In Europe, the European
Commission has taken the position that feces are
uncontestably a tissue, but it does not naturally fall under
the EUTCD.59 Accordingly, the competent authorities have
avoided common European definitions, leaving the regula-
tion to be managed at a national enforcement level. Mem-
ber states are free to create specific regulatory frameworks
or apply existing regulatory frameworks, such as national
requirements for tissue and cell transplantation.59 Conse-
quently, this leaves FMT largely unregulated in many
European countries. In countries where specific legislation
has been adopted, FMT is regulated as either a tissue or
a drug.
The regulatory controversy revolves around whether
feces are of nonhuman origin and therefore considered a
drug or of human origin and therefore considered a tissue.
The EUTCD committee recognizes that feces fulfill the
criteria of being a tissue, but because the active substances
in feces, that is, microbes and their products, are of non-
human origin, they argue that feces cannot be covered by
the EUTCD.59 This view, however, may prove too narrow.
The human microbiota has evolved over millions of years
through coexistence with humans and is highly specific to
the individual; therefore, it can easily be argued that the
microbiota constitutes an integral part of the human body.
In addition to microorganisms, epithelial cells shed from
the gastrointestinal tract lining as well as immunoglobulins
and metabolites are present in feces.60 If and how these
constituents contribute to the clinical effects of FMT is
unknown, but it remains clear that they are also transferred
during an FMT.60
Regulating FMT as a drug addresses the demand for
safety, but the strict requirements for a reproducible prod-
uct consistent in all its substances, which is inherent in drug
legislation, is a requirement that donor microbiota cannot
fulfill because of their individual and variable nature. The
current drug legislation provides no legal basis to cover
donor-related aspects or long-term traceability. The safety
of FMT highly depends on the selection and screening of
the donor because no standardization of the product exists
and because pathogen reduction, such as that used for
plasma-derived products, is inherently impossible for
FMT products. Thus, for a single-donor procedure with
unprocessed donor feces, drug legislation does not meet the
key requirements for regulation.
Classifying FMT as a tissue would result in regulation
allowing a variable product and would also cover the activi-
ties related to obtaining the product, as described above.
This also applies at the organizational level, imposing
requirements for donor selection, safe handling, documen-
tation, and long-term traceability.
Depending on the organizational and financial struc-
tures of national health care systems, different countries
may need to apply FMT regulations differently. Regulatory
frameworks designed to fit, for example, the Scandinavian
welfare model with public hospitals and free access to hos-
pital services without charge to citizens would not work in
countries with privately owned hospitals where patients pay
out of pocket for hospital services. This renders the US IND
model, which is necessary in a “for-profit” system, unfit in
areas such as Scandinavia. To accommodate these differ-
ences, different approaches, such as those used for blood
products, may be needed to sufficiently secure FMT for
patients in different countries.
THE BLOOD SERVICE INFRASTRUCTURE
AS A SUPERIOR PLATFORM
The requirements for an effective feces bank infrastructure
parallel those of a blood service infrastructure. Blood service
organizations handle donor recruitment and blood pres-
creening and screening, donation collection, processing,
release, and storage. Adding stool collection to the blood
service infrastructure may present a new opportunity for
blood banks that already have well-established procedures,
such as inspections on a regular basis from the health
authorities.
Blood donors are a highly specific group of healthy
people who have already volunteered to donate blood to
help other human beings; therefore, they are more likely to
volunteer and be eligible for feces donations. In a previous
study, we found that 88% of blood donors who were asked
to become feces donors were willing to do so.47 Notably, we
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also demonstrated that blood donors had an approximately
20% eligibility rate,47 which was high compared with rates
reported from other settings where feces donors were rec-
ruited outside of blood banks.52 In general, most screened
participants fail the screenings due to the age criteria, high
body mass index, and allergies.45,47,52 The main determi-
nants of a high blood donor eligibility rate are their willing-
ness to become feces donors, the absence of risk factors,
and a low failure rate during the feces screening.47 (For
screening criteria, see Table S1). In practice, the recruitment
process among blood donors ensures a scalable flow of
healthy feces donors to meet the clinical demand for FMT.
With the blood bank infrastructure, FMT is scalable. Cur-
rently, FMT institutions operate within limits imposed by prac-
tical and economic barriers, and there is a strong economic
argument (economies of scale and scope) for aligning FMT
services with current blood bank organizations.
PERSPECTIVE
In this paper, we argue that existing blood services possess
most of the infrastructure necessary to run and maintain a
high-capacity FMT service. Currently, without appropriate
legislation, FMT stands as a highly effective treatment caught
in a regulatory dispute. Agreement on an applicable regula-
tory framework is imminent, but the continuous develop-
ment of microbiota-based therapies makes it difficult for
authorities to determine the most appropriate legislation.
Regulation by competent authorities should mainly ensure a
high degree of safety. At the same time, flexibility is required
to ensure patient access to effective treatments, continuing
innovation, and the investigation of new ideas. A European
consensus that FMT is best regulated as a tissue transfer is
emerging.46,61,62 While tissue transfer regulation may apply to
unprocessed, donor-specific, cryopreserved feces, the manip-
ulation or standardization of feces into a well-defined sub-
stance makes the resulting product ideal for the drug
legislation.44 At the current stage, where we speculate that
the combination of several different components ensures
the high success rate of the treatment against CD infection,
there is an urgent need to regulate the procedure under the
tissue and cells legislation. If effective treatments based on
well-defined and controlled preparations of bacteria, bacte-
riophages, bacterial metabolites, or immune system compo-
nents become available, such treatments should be regulated
under drug legislation. Currently, a clear regulatory definition
of when tissue becomes a drug is crucial.
With an estimated 700,000 cases of CD infection annu-
ally in Europe and the United States,63 FMT is an emerging
therapy with the potential to become routine practice. Fulfill-
ing a demand of this scale requires an extensive and robust
infrastructure. Blood service organizations are suitable to per-
form the recruitment, prescreening, and screening of donors,
as well as the processing and storage of the products. We
have developed an effective FMT service through a fruitful
collaboration between the blood service center and the
department of hepatology and gastroenterology, assuring a
high level of safety; therefore, we propose that FMT may rep-
resent a new frontier for blood banks.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
TABLE S1. Content of the fecal donor screening used to
screen blood donors.
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